TY - JOUR
T1 - Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease
AU - Hartman, Corina
AU - Berkowitz, Drora
AU - Weiss, Batia
AU - Shaoul, Ron
AU - Levine, Arie
AU - Adiv, Orly Eshach
AU - Shapira, Riki
AU - Fradkin, Akiva
AU - Wilschanski, Michael
AU - Tamir, Ada
AU - Shamir, Raanan
PY - 2008/7
Y1 - 2008/7
N2 - Background: A polymeric diet rich in transforming growth factor-beta 2 used as a single nutrient has been shown to induce remission in 79% of children with Crohn's disease. Objectives: To summarize the experience of several pediatric gastroenterology units in Israel using a TGFβ2-enriched polymeric diet (Modulen IBD®) supplementation in children and adolescents with Crohn's disease. Methods: In a retrospective study we reviewed the charts of 28 children with Crohn's disease (10 girls, 18 boys) who received, in addition to conventional treatment, Modulen IBD as a supplement to their regular nutrition. These children were compared with 18 children supplemented with standard polymeric formula (Ensure Plus®) and 18 children without formula supplementation. We recorded clinical manifestations, growth, and the Pediatric Crohn's Disease Activity Index before and after initiation of the polymeric diet. Results: The Modulen-treated children showed a significant decrease in PCDAI from 34.3 to 15.7 (P < 0.0001). A significant decrease in PCDAI was recorded also in the Ensure Plus group, from 35 to 22 (P = 0.02) but not in the non-supplemented group. Significant improvements in body mass index (P = 0.01) and erythrocyte sedimentation rate (P = 0.03) were recorded at follow-up (median 3.4 months) only in the Modulen IBD group. Conclusions: In this cohort of children with Crohn's disease, supplementation of the diet with Modulen IBD as well as supplementation with Ensure Plus was associated with a decrease in PCDAI. The children supplemented with Modulen IBD also showed improvement in BMI, suggesting an additional advantage of nutritional therapy in children with this disease.
AB - Background: A polymeric diet rich in transforming growth factor-beta 2 used as a single nutrient has been shown to induce remission in 79% of children with Crohn's disease. Objectives: To summarize the experience of several pediatric gastroenterology units in Israel using a TGFβ2-enriched polymeric diet (Modulen IBD®) supplementation in children and adolescents with Crohn's disease. Methods: In a retrospective study we reviewed the charts of 28 children with Crohn's disease (10 girls, 18 boys) who received, in addition to conventional treatment, Modulen IBD as a supplement to their regular nutrition. These children were compared with 18 children supplemented with standard polymeric formula (Ensure Plus®) and 18 children without formula supplementation. We recorded clinical manifestations, growth, and the Pediatric Crohn's Disease Activity Index before and after initiation of the polymeric diet. Results: The Modulen-treated children showed a significant decrease in PCDAI from 34.3 to 15.7 (P < 0.0001). A significant decrease in PCDAI was recorded also in the Ensure Plus group, from 35 to 22 (P = 0.02) but not in the non-supplemented group. Significant improvements in body mass index (P = 0.01) and erythrocyte sedimentation rate (P = 0.03) were recorded at follow-up (median 3.4 months) only in the Modulen IBD group. Conclusions: In this cohort of children with Crohn's disease, supplementation of the diet with Modulen IBD as well as supplementation with Ensure Plus was associated with a decrease in PCDAI. The children supplemented with Modulen IBD also showed improvement in BMI, suggesting an additional advantage of nutritional therapy in children with this disease.
KW - Children
KW - Crohn's disease
KW - Nutritional therapy
KW - Transforming growth factor-beta
UR - http://www.scopus.com/inward/record.url?scp=52049087901&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18751627
AN - SCOPUS:52049087901
SN - 1565-1088
VL - 10
SP - 503
EP - 507
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 7
ER -